Answers are grounded in this paper and cite their sources.
The European Medicines Agency aims to make patient-level data from clinical trials publicly accessible while protecting privacy; this would improve drug-development efficiency, cost-effectiveness, and comparative-effectiveness analysis and reduce duplication of effort.
No takes yet. Share an insight, caveat, or question.
Eichler et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: